Relapse Prevention With Varenicline

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

104 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-10-31

Study Completion Date

2011-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to determine if varenicline (Chantix®), currently used as a smoking cessation aid, will decrease the likelihood of relapse to smoking following a programmed lapse in the laboratory. The hypothesis is that varenicline will reduce the reinforcing effects of smoking and will delay or prevent relapse compared to placebo.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Chantix on Relapse Prevention for Smoking Cessation

NCT00948649

Nicotine Dependence

COMPLETED PHASE4

The Effect of Varenicline (Chantix) and Bupropion (Zyban) on Smoking Lapse Behavior

NCT00580853

Smoking Lapse Behavior

COMPLETED PHASE2

Varenicline (Chantix™) for the Treatment of Alcohol Dependence

NCT00705523

Alcoholism

COMPLETED PHASE2

Combining Varenicline and Bupropion for Smoking Cessation

NCT00943618

Smoking Cessation

COMPLETED PHASE3

Varenicline OTC Trial on Efficacy and Safety

NCT03557294

Tobacco Dependence Withdrawal Symptoms Smoking Cessation

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this study, the investigators plan to use an experimental model of a lapse, in which volunteers smoke two cigarettes after a brief period of (12-24 hours). The goals of this study are to assess the impact of varenicline on the subjective and reinforcing effects of cigarettes, as well as the latency to resume smoking (relapse) following the lapse exposure.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Recurrence Smoking Cessation Substance-Related Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Group given placebo.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo given twice a day or five weeks.

Varenicline

Experimental group given varenicline dosing.

Group Type EXPERIMENTAL

Varenicline

Intervention Type DRUG

Varenicline given twice a day or five weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Varenicline

Varenicline given twice a day or five weeks.

Intervention Type DRUG

Placebo

Placebo given twice a day or five weeks.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Varenicline (Chantix®)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18-75 years old
* Reports smoking at least 10 cigarettes per day AND provides a urine sample that tests positive for nicotine metabolites at intake
* Contemplating a smoking cessation attempt in the near future
* Willing to engage in a practice quit attempt during which they will be asked to smoke on one occasion
* Able to give informed consent

Exclusion Criteria

* Currently meets Diagnostic and Statistical Manual (DSM-IV) criteria for depression, bi-polar disorder, or schizophrenia
* History of attempted suicide or expresses any current suicidal ideation
* Pregnant, breast feeding, or planning to become pregnant within the next 3 months
* Reports desire for immediate treatment of tobacco/nicotine dependence
* Severe impairment of renal function indicated by Glomerular Filtration Rate (GFR) less than 30 ml/min calculated using the Cockcroft and Gault prediction method (plasma creatinine adjusted by weight, gender, and age)

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes